Suven Life Sciences Completes Preferential Allotment and Strengthens Governance with Director Re-appointment

Suven Life Sciences Completes Preferential Allotment and Strengthens Governance with Director Re-appointment​

Suven Life Sciences Limited announced a significant recapitalization event following its Board of Directors meeting on July 8, 2026. The company approved the conversion and allotment of equity shares resulting from fully paid warrants, received consideration for the transaction, appointed an independent director, and commenced the incorporation of a new wholly owned subsidiary in Singapore.

The Board formally approved the conversion of 1,85,70,133 fully paid warrants into 1,85,70,133 equity shares of Rs. 1/- each. These shares were issued to various Non-Promoter Persons and Entities on a preferential basis at an issue price of Rs. 134/- per share.

The aggregate consideration received from the allottees amounted to Rs. 248,83,97,822/- upon the conversion. The allotment encompassed 17 non-promoter entities. Details of the allotments are as follows:


The allotment led to an increase in the company's paid-up equity share capital. The total number of shares post-issue reached 282,56,2686, corresponding to a paid-up capital of Rs. 28,25,62,686/-. Prior to this transaction, the subscribed and paid-up capital stood at 26,39,92,553 with 263,99,2553 equity shares.

Governance and Subsidiary Incorporation Updates​

In a governance move, the Board of Directors approved the re-appointment of Dr. Vajja Sambasiva Rao as a Non-Executive Independent Director for a second term. The appointment is effective from January 21, 2027, for a tenure of five years, concluding on January 20, 2032, subject to member approval at the ensuing Annual General Meeting. Dr. Vajja Sambasiva Rao holds a Master of Science and Ph.D Chemistry from BITS Pilani and has extensive experience in chemistry, governance, project and financial management.

Additionally, the company is incorporating Suven Neurosciences Pte. Ltd., a Wholly Owned Subsidiary (WOS) to be based in Singapore. This subsidiary will operate in the Bio-Pharmaceutical and clinical development industry, focusing on the acquisition, development, and commercialization of novel therapeutics for neurological and other disorders. The total investment amount for this WOS is up to USD 100.00 Mn, at a subscription price of USD 1.00 per share, representing 100% shareholding by Suven Life Sciences Limited.

SUVEN Stock Price Movement​

Shares of Suven Life Sciences Limited today slipped by 0.16% to settle at ₹317.10. The stock was traded on a volume of 1.44 million shares, finishing higher than its intraday low of ₹312.05.